Intellia (NTLA) FDA accepts Lonvo-z BLA for hereditary angioedema
Intellia Therapeutics said the FDA accepted its biologics license application for Lonvoguran ziclumeran (Lonvo-z) for hereditary angioedema and granted priority review.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.